modafinil has been researched along with Bilateral Headache in 18 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 12-month, open-label, flexible-dose study with an extension period evaluated the tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy." | 9.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 9.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 9.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| "This 12-month, open-label, flexible-dose study with an extension period evaluated the tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy." | 5.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 5.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 5.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| " Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon." | 2.82 | Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study. ( Amchin, J; Frye, MA; Gross, N; Ketter, TA, 2016) |
| "Past modafinil use was reported by 2." | 2.74 | Modafinil and zolpidem use by emergency medicine residents. ( Ankel, FK; Asplin, BR; Flottemesch, TJ; Ling, LJ; Mason, EJ; McBeth, BD; McNamara, RM, 2009) |
| "Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0." | 2.72 | Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. ( Alamy, S; Connor, K; Davidson, JR; Gadde, K; Vaishnavi, S; Zhang, W, 2006) |
| "Treatment with modafinil, as compared with placebo, resulted in a modest improvement from baseline in mean (+/-SEM) nighttime sleep latency (the interval between the time a person attempts to fall asleep and the onset of sleep) (1." | 2.71 | Modafinil for excessive sleepiness associated with shift-work sleep disorder. ( Arora, S; Czeisler, CA; Dinges, DF; Hughes, RJ; Kingsbury, L; Niebler, GE; Roth, T; Schwartz, JR; Walsh, JK; Wright, KP, 2005) |
| "Modafinil or a placebo was administered once daily for 7 days." | 2.69 | A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. ( Grebow, PE; Hartman, LN; King, SP; Laughton, WB; McCormick, GC; Simcoe, D; Wong, YN, 1999) |
| "Modafinil was well tolerated at a single oral dose of 200 mg." | 2.69 | Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. ( Gorman, S; Grebow, P; King, SP; Laughton, W; McCormick, GC; Simcoe, D; Wong, YN, 1999) |
| "Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine." | 2.66 | Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. ( Dinis-Oliveira, RJ; Sousa, A, 2020) |
| "Modafinil was the most common drug used as a first-line treatment (93%) and in combination therapy (70%)." | 1.48 | Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. ( D'ancona, G; Drakatos, P; Kent, BD; Leschziner, GD; Nesbitt, A; Patel, K; Rosenzweig, I; Selsick, H; Steier, J; Thakrar, C; Williams, AJ, 2018) |
| "Modafinil (Provigil) is a wake-promoting drug approved for patients with narcolepsy or other causes of excessive daytime sleepiness." | 1.35 | Unsuccessful suicide attempt of a 15 year old adolescent with ingestion of 5000 mg modafinil. ( Neuman, G; Pillar, G; Shehadeh, N, 2009) |
| "In modafinil-treated patients, clinically significant increases in diastolic or systolic blood pressure were infrequent (n = 9 and n = 1, respectively, < 1% of patients)." | 1.34 | Evaluation of the safety of modafinil for treatment of excessive sleepiness. ( Arora, S; Dayno, JM; Erman, MK; Hirshkowitz, M; Roth, T; Schwartz, JR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Sousa, A | 1 |
| Dinis-Oliveira, RJ | 1 |
| Thakrar, C | 1 |
| Patel, K | 1 |
| D'ancona, G | 1 |
| Kent, BD | 1 |
| Nesbitt, A | 1 |
| Selsick, H | 1 |
| Steier, J | 1 |
| Rosenzweig, I | 1 |
| Williams, AJ | 1 |
| Leschziner, GD | 1 |
| Drakatos, P | 1 |
| Kinslow, CJ | 2 |
| Shapiro, SD | 1 |
| Grunebaum, MF | 1 |
| Miller, EC | 2 |
| Shalom Feinberg, S | 1 |
| Ooi, T | 1 |
| Wong, SH | 1 |
| See, B | 1 |
| Ketter, TA | 1 |
| Amchin, J | 1 |
| Frye, MA | 1 |
| Gross, N | 1 |
| Neuman, G | 1 |
| Shehadeh, N | 1 |
| Pillar, G | 1 |
| McBeth, BD | 1 |
| McNamara, RM | 1 |
| Ankel, FK | 1 |
| Mason, EJ | 1 |
| Ling, LJ | 1 |
| Flottemesch, TJ | 1 |
| Asplin, BR | 1 |
| Schwartz, JR | 3 |
| Khan, A | 1 |
| McCall, WV | 1 |
| Weintraub, J | 1 |
| Tiller, J | 2 |
| Black, JE | 1 |
| Hull, SG | 1 |
| Yang, R | 1 |
| Harsh, JR | 1 |
| Czeisler, CA | 1 |
| Walsh, JK | 1 |
| Roth, T | 2 |
| Hughes, RJ | 1 |
| Wright, KP | 1 |
| Kingsbury, L | 1 |
| Arora, S | 2 |
| Niebler, GE | 1 |
| Dinges, DF | 1 |
| Vaishnavi, S | 1 |
| Gadde, K | 1 |
| Alamy, S | 1 |
| Zhang, W | 1 |
| Connor, K | 1 |
| Davidson, JR | 1 |
| Hirshkowitz, M | 1 |
| Erman, MK | 1 |
| Dayno, JM | 1 |
| Dunlop, BW | 1 |
| Crits-Christoph, P | 1 |
| Evans, DL | 1 |
| Hirschowitz, J | 1 |
| Solvason, HB | 1 |
| Rickels, K | 1 |
| Garlow, SJ | 1 |
| Gallop, RJ | 1 |
| Ninan, PT | 1 |
| Wong, YN | 2 |
| Simcoe, D | 2 |
| Hartman, LN | 1 |
| Laughton, WB | 1 |
| King, SP | 2 |
| McCormick, GC | 2 |
| Grebow, PE | 1 |
| Gorman, S | 1 |
| Laughton, W | 1 |
| Grebow, P | 1 |
| Elovic, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Operational Evaluation of a Photic Countermeasure to Improve Alertness, Performance, and Mood During Nightshift Work on a 105-day Simulated Human Exploration Mission to Mars[NCT01169233] | 25 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for modafinil and Bilateral Headache
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.
Topics: Anxiety; Diarrhea; Drug Eruptions; Drug Interactions; Erythema Multiforme; Forensic Sciences; Headac | 2020 |
Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature.
Topics: Adult; Drug Synergism; Drug Therapy, Combination; Female; Headache; Humans; Hypertension; Modafinil; | 2018 |
Use of provigil for underarousal following TBI.
Topics: Arousal; Benzhydryl Compounds; Brain Injuries; Central Nervous System Stimulants; Clinical Trials as | 2000 |
9 trials available for modafinil and Bilateral Headache
| Article | Year |
|---|---|
Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study.
Topics: Adult; Aged; Anxiety; Benzhydryl Compounds; Bipolar Disorder; Double-Blind Method; Female; Headache; | 2016 |
Modafinil and zolpidem use by emergency medicine residents.
Topics: Adult; Akathisia, Drug-Induced; Amnesia; Anorexia; Benzhydryl Compounds; Central Nervous System Stim | 2009 |
Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Follow-Up Studies; Hea | 2010 |
The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; | 2010 |
Modafinil for excessive sleepiness associated with shift-work sleep disorder.
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive So | 2005 |
Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder; Disorders | 2006 |
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2007 |
A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
Topics: Adolescent; Adult; Anxiety; Area Under Curve; Benzhydryl Compounds; Central Nervous System Stimulant | 1999 |
Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects.
Topics: Adult; Age Factors; Aged; Area Under Curve; Benzhydryl Compounds; Central Nervous System Stimulants; | 1999 |
6 other studies available for modafinil and Bilateral Headache
| Article | Year |
|---|---|
Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice.
Topics: Adult; Central Nervous System Stimulants; Drug Therapy, Combination; Female; Follow-Up Studies; Head | 2018 |
In Reply: Spontaneous MAOI hypertensive reaction, not likely armodafinil - tranylcypromine interaction.
Topics: Headache; Humans; Hypertension; Modafinil; Monoamine Oxidase Inhibitors; Tranylcypromine | 2019 |
Spontaneous MAOI hypertensive reaction, not likely armodafinil -tranylcypromine interaction.
Topics: Headache; Humans; Hypertension; Modafinil; Monoamine Oxidase Inhibitors; Tranylcypromine | 2019 |
Modafinil as a Stimulant for Military Aviators.
Topics: Accidents, Aviation; Adult; Aerospace Medicine; Anxiety; Central Nervous System Stimulants; Diarrhea | 2019 |
Unsuccessful suicide attempt of a 15 year old adolescent with ingestion of 5000 mg modafinil.
Topics: Abdominal Pain; Adolescent; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Overdose; | 2009 |
Evaluation of the safety of modafinil for treatment of excessive sleepiness.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; | 2007 |